Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Decker, William K ^a   Shah, Nina ^b   Xing, Dongxia ^b   Lapushin, Ruth ^b   Li, Sufang ^b   Robinson, Simon N ^b   Yang, Hong ^b   Parmar, Simrit ^b   Halpert, Matthew M ^a   Keating, Michael J ^b   Gribben, John G ^c   Molldrem, Jeffrey J ^b   Shpall, Elizabeth J ^b   Wierda, William G ^b   Shiku, Hiroshi ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD40 LIGAND; CHROMIUM 51; GAMMA INTERFERON;

ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CELL DEATH; CELL SPECIFICITY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VIVO STUDY; NONHUMAN; SEPARATION TECHNIQUE;

ADULT; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD40; ANTIGENS, NEOPLASM; FEASIBILITY STUDIES; FETAL BLOOD; HLA ANTIGENS; HUMANS; IMMUNOLOGICAL SYNAPSES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; T-LYMPHOCYTES;

MUS;

EID: 84871294655     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051390     Document Type: Article

References (42)

1. Chen J, McMillan NAJ, (2008) Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukemia. Cancer Biol Ther 7: 174-179.
2. Nabhan C, Shanafelt TD, Kay NE, (2008) Controversies in the front-line management of chronic lymphocytic leukemia. Leukemia Res 32: 679-688.
3. Shah N, Decker WK, Lapushin R, Xing D, Robinson SN, et al. (2011) HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiologic immune surveillance. Leukemia 25: 1036-1039.
4. Ben-Bassat I, Raanani P, Gale RP, (2007) Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant 39: 441-446.
5. Gribben JG, (2008) Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant 15: 53-58.
6. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, et al. (2005) Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106: 4389-4396.
7. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, et al. (2004) Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32: 28-35.
8. Ritgen M, Bottcher S, Stilgenbauer S, Bunjes D, Schubert J, et al. (2008) Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia 22: 1377-1386.
9. Kater AP, van Oers MHJ, Kipps TJ, (2007) Cellular immune therapy for chronic lymphocytic leukemia. Blood 110: 2811-2818.
10. Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, et al. (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6: 667-672.
11. Mayr C, Kofler DM, Buning H, Bund D, Hallek M, et al. (2005) Transduction of CLL cells by CD40 ligand enhances antigen-specific immune recognition by autologous T cells. Blood 106: 3223-3226.
12. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, et al. (2003) Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102: 571-576.
13. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, et al. (2002) Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100: 2123-2131.
14. Hus I, Rolinski J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, et al. (2005) Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19: 1621-1627.
15. Mous R, Savage P, Remmerswaal EB, van Lier RA, Eldering E, et al. (2006) Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes. Leukemia 20: 1096-1102.
16. Kater AP, Remmerswaal EB, Nolte MA, Eldering E, van Oers MH, et al. (2004) Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. Br J Haematol 126: 512-516.
17. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, et al. (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96: 2917-2924.
18. Kato K, Cantwell MJ, Sharma S, Kipps TJ, (1998) Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 101: 133-141.
19. Dilloo D, Brown M, Roskrow M, Zhong W, Hollladay M, et al. (1997) CD40 ligand induces an antileukemia immune response in vivo. Blood 90: 1927-1933.
20. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, et al. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118: 2427-2437.
21. Hamblin AD, Hamblin TJ, (2008) The immunodeficiency of chronic lymphocytic leukemia. Br Med Bull 87: 49-62.
22. Le Dieu R, Gribben J, (2006) Vaccine- and immune-based therapy in chronic lymphocytic leukemia. Semin Oncol 33: 220-229.
23. Ramsay AG, Xing D, Decker WK, Burks JK, Wierda WG, et al. (2008) Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells. Blood 112: 2333a.
24. McClune BL, Defor T, Brunstein C, Vogel RI, Majhail NS, et al. (2012) Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. Br J Haematol 156: 273-275.
25. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, et al. (2009) Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for Blood and Marrow transplantation. J Clin Oncol 27: 256-263.
26. Decker WK, Xing D, Li S, Robinson SN, Yang H, et al. (2006) Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine 24: 3203-3216.
27. Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, et al. (2010) Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 ex vivo expansion. J Immunother 33: 684-696.
28. Parmar S, Robinson SN, Komanduri K, St. John L, Decker W, et al. (2006) Ex vivo expanded umbilical cord blood T-cells maintain naïve phenotype and TCR diversity. Cytotherapy 8: 149-57.
29. Bagnara D, Kaufman MS, Calissano C, Marsillo S, Patten P, et al. (2011) A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 117: 5463-5472.
30. King MA, Covassin L, Brehm MA, Racki W, Pearson T, et al. (2009) Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host like disease and the role of host major histocompatibility complex. Clin Exp Immunol 157: 104-118.
31. Nishida T, Hudecek M, Kostic A, Bleakley M, Warren EH, et al. (2009) Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia. Clin Cancer Res 15: 4759-4768.
32. Rudolph JM, Eickel N, Haller C, Schindler M, Fackler OT, (2009) Inhibition of T-cell receptor-induced actin remodeling and relocalization of Lck are evolutionarily conserved activities of lentiviral Nef proteins. J Virol 83: 11528-11539.
33. Wolf D, Giese SI, Witte V, Krautkramer E, Trapp S, et al. (2008) Novel (n)PKC kinases phosphorylate Nef for increased HIV transcription, replication and perinuclear targeting. Virology 370: 45-54.
34. Haller C, Rauch S, Fackler OT, (2007) HIV-1 Nef employs two distinct mechanisms to modulate Lck subcellular localization and TCR induced actin remodeling. PLoS One 21: e1212.
35. Miscia S, Di Baldessarre A, Sabatino G, Bonvini E, Rana RA, et al. (1999) Inefficient phospholipase C activation and reduced Lck expression characterize the signaling defect of umbilical cord T lymphocytes. J Immunol 163: 2416-2424.
36. Bachmann MF, Gallimore A, Linkert S, Cerundolo V, Lanzavecchia A, et al. (1999) Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naïve and memory T cells. J Exp Med 189: 1521-1530.
37. Hoogendorn M, Wolbers JO, Smit WM, Schaafsma MR, Barge RM, et al. (2004) Generation of B-cell chromic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy. Leukemia 18: 1278-1287.
38. Mavroudis DA, Dermime S, Molldrem J, Jiang YZ, Raptis A, et al. (1998) Specfic depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reactions. Br J Haematol 101: 565-570.
39. Martins SL, St. John LS, Champlin RE, Wieder ED, McMannis J, et al. (2004) Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104: 3429-3436.
40. Samarasinghe S, Mancao C, Pule M, Nawroly N, Karlsson H, et al. (2010) Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood 115: 396-407.
41. Porter DL, Levine BL, Kalos M, Bagg A, June CH, (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 723-733.
42. Miller JS, Soigner Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105: 3051-3057.